Arcus Biosciences vs Xencor
RCUS and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RCUS and XNCR compare
Xencor is the larger company, worth 1.2 times as much as Arcus Biosciences ($2.6B against $2.1B).
Xencor grew revenue faster over the last twelve months (−28.6% versus −55.3% for Arcus Biosciences).
Xencor keeps more of each dollar of sales as profit, with a net margin of −156% compared with −393% at Arcus Biosciences.
Xencor scores higher on the StockData Score (5 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RCUS | XNCR |
|---|---|---|
| Size and price | ||
| Market cap | $2.1B | $2.6B |
| Share price | $16.39 | $34.50 |
| Change, 1 year | −18.3% | 131% |
| Change, 5 years | −64.6% | −2.7% |
| Beta (5Y) | 1.13 | −0.05 |
| Employees | 601 | 260 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 17.8× (better) | 24.4× |
| P/B | 4.5× (better) | 5.1× |
| FCF yield | −22.8% | −8.1% (better) |
| Fair value | $7.34 | $11.73 |
| Margin of safety | −123% (better) | −194% |
| Growth | ||
| Revenue growth (TTM) | −55.3% | −28.6% (better) |
| Revenue growth, 5Y average | 25.9% (better) | 0.47% |
| Profitability | ||
| Operating margin | −415% | −206% (better) |
| Net margin | −393% | −156% (better) |
| FCF margin | −406% | −198% (better) |
| Return on equity | −90.8% | −29.1% (better) |
| Return on invested capital | – | −26.6% |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −44.2× | −8.0× (better) |
| Current ratio | 3.82 | 6.39 (better) |
| Altman Z-score | −0.74 | 5.01 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −13.8% | – |
| Shareholder yield | −13.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 96.3% | 113% |
| Held by insiders | 31.7% | 1.6% |
| Insider net buying, 12 months | −$9.3M | −$7.5M (better) |
| Short interest, % of float | 15.2% | 17.6% |
Go deeper
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.